Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer (UGIH09067)

This study has been completed.
Information provided by (Responsible Party):
University of Rochester Identifier:
First received: August 9, 2010
Last updated: January 31, 2013
Last verified: January 2013
The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.

Condition Intervention Phase
Biliary Tract Cancer
Gallbladder Cancer
Drug: Panitumumab
Drug: oxaliplatin
Drug: gemcitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer

Resource links provided by NLM:

Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • To determine the radiographic response rate of GEMOX-Panitumumab (GEMOX-P) in chemotherapy naïve KRAS/ BRAF wild type stage IV BTC [ Time Frame: Evaluation at every 8 weeks and thereafter. Responses must be ] [ Designated as safety issue: No ]
    Tumor measurement - same imaging modality used in pre-treatment evaluation - include radiological examination of all areas with affected disease. For pretreatment and at the end of cycle 2 CT scans (chest/abdomen/pelvis) will be used. For all subsequent cycles, CT of chest/abdomen/pelvis will be used every 8 weeks.

Secondary Outcome Measures:
  • Evaluate the toxicities of GEMOX-P regimen in this population. Evaluate the preliminary efficacy of GEMOX-P regimen including progression free survival, and overall survival in this population. [ Time Frame: Patients will be followed until death ] [ Designated as safety issue: Yes ]
    Any adverse event continuing after the study completion and considered potentially related to study treatment will be followed until resolution, stabilization or initiation of treatment that confounds the ability to assess the event

Enrollment: 30
Study Start Date: December 2010
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Panitumumab
Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
Drug: Panitumumab
Day 1 and 15 = 6 mg/kg IV
Other Name: GEMOX-Panitumumab (GEMOX-P)
Drug: oxaliplatin
Days 1 and 15 = 85mg/m2 IV
Drug: gemcitabine
Days 1 and 15 = 1000 mg/m2 IV


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed metastatic or unresectable Kras and Braf wild-type biliary tract adenocarcinoma (bile ducts, hepatic duct, cystic duct, common bile duct, ampulla of Vater or gallbladder adenocarcinoma).
  • Screening for tumor Kras and Braf mutations requires formalin fixed paraffin embedded tumor blocks from core needle excisional biopsy.
  • Participants must have measurable disease.
  • No prior chemotherapy for biliary tract or gallbladder cancer. Prior chemoembolization or radiation to the liver allowed as long as measurable disease outside chemoembolization or radiation area and other baseline characteristics met and at least 4 weeks has lapsed since therapy. No prior gemcitabine or oxaliplatin or anti-EGFR therapies including panitumumab therapy allowed.
  • Age minimum 18 years old.
  • Life expectancy of greater than 3 months.
  • ECOG performance status < 1
  • Participants must have normal organ and marrow function as defined below:
  • Leukocytes > 3,000/mcL Absolute neutrophil count > 1,500/mcL Platelets > 100,000/mcL hemoglobin > 9mg/dL Mg > 1.2 mEq/L total bilirubin < 2.5 mg/dL AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal (unless liver is involved with tumor, in which case the transaminases must be 5 x upper limits of normal), creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels about institutional normal
  • Patients with concurrent malignancy may be included if disease is characterized by one of the following definitions: 1. Malignancy treated with curative intent and with no known active disease present for 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician. 2. Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease. 3. Adequately treated cervical carcinoma in situ without evidence of disease. 4. Prostatic intraepithelial neoplasia without evidence of prostate cancer. 5. DCIS without evidence of breast cancer.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Patients may have prior placement of stents or shunts to relieve biliary obstruction.

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Participants may not be receiving any other study agents.
  • Participants with known brain metastases.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, oxaliplatin or panitumumab.
  • Patients with preexisting peripheral neuropathy of grade 2 or greater severity according to the Common Terminology Criteria of the NCI (version 3.0) are ineligible.
  • Patients with biliary obstruction with inadequate drainage and total bilirubin > 2.5 mg/dL are ineligible.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements,
  • History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
  • Known positive test(s) for HIV, hepatitis C virus, acute or chronic active hepatitis B infection.
  • Pregnant women are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01308840

United States, Massachusetts
Dana-Farber / Harvard Cancer Center
Boston, Massachusetts, United States, 02215
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Principal Investigator: Aram Hezel, MD University of Rochester
  More Information

Responsible Party: University of Rochester Identifier: NCT01308840     History of Changes
Other Study ID Numbers: UGIH09067 
Study First Received: August 9, 2010
Last Updated: January 31, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Rochester:
biliary tract
gallbladder cancer

Additional relevant MeSH terms:
Biliary Tract Neoplasms
Gallbladder Neoplasms
Biliary Tract Diseases
Digestive System Diseases
Digestive System Neoplasms
Gallbladder Diseases
Neoplasms by Site
Antibodies, Monoclonal
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 26, 2016